Brief: Active Biotech Q1 Loss Widens To SEK 15.7 Million
21/04/2022 07:33
April 21 (Reuters) - Active Biotech AB publ ACTI.ST :
* REG-ACTIVE BIOTECH INTERIM REPORT Q1 2022
* Q1 OPERATING LOSS SEK 15,3 MILLION VERSUS LOSS SEK SEK 9.7
MILLION YEAR AGO
* Q1 LOSS AFTER TAX SEK 15,7 MILLION VERSUS VERSUS LOSS SEK
9,8
MILLION YEAR AGO
Source text for Eikon: ID:nGNE86bfwC
Further company coverage: ACTI.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Active Biotech AB publ
See all newsBrief: Active Biotech Says Japan Grants Patent For Laquinimod Ophthalmic Formulation
Brief: Active Biotech Reports Q2 Operating Profit Of SEK -10.2 Mln
Brief: Active Biotech Expands U.S. Collaboration
Brief: Active Biotech Gets Approval To Resume Enrolment In Hovon 172 MF Study
Brief: Active Biotech Q1 Loss After Tax At SEK 8.4 Million